Tyrosine kinase inhibitorPhase 3 trialInvestigational
Selpercatinib
How it works
Blocks the RET, ROS1, and ALK receptors on cancer cells, preventing growth signals.
Cancer types
Lung Cancer— RET-mutated, ROS1-mutated, ALK-positive
Efficacy
In clinical trials, selpercatinib improved progression-free survival in patients with RET-mutated, ROS1-mutated, or ALK-positive non-small cell lung cancer, with a median progression-free survival of approximately 16.4 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Patient Resists Treatment with RET Inhibitor for Pancreatic Cancer | Pancreatic Cancer | observational | — | Source → |
| Selpercatinib May Cause Severe Hypersensitivity in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| New Study Compares Selpercatinib to Chemotherapy in Lung Cancer Patients | Lung Cancer | phase-3 | The median progression-free survival was 24.8 months with selpercatinib and 11.2 months with control treatment. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.